Biomea Fusion, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 28, 2023. Biomea Fusion is a clinical-stage biotechnology company developing covalent small-molecule drugs for genetically defined cancers and metabolic diseases. It had no approved products and generated no revenue.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $62.7 million | $28.0 million |
| General and administrative expense | $20.9 million | $13.7 million |
| Total operating expenses | $83.6 million | $41.7 million |
| Net loss | $81.8 million | $41.6 million |
| Net loss per share, basic and diluted | $2.80 | $1.74 |
| Cash used in operating activities | $62.4 million | $35.4 million |
- Fourth-quarter 2022 net loss was $25.3 million; operating expenses were $26.3 million.
- At year-end, cash and cash equivalents were $111.9 million, short-term investments $1.2 million, and restricted cash $0.4 million. The company reported total assets of $129.3 million, total liabilities of $20.8 million, and stockholders’ equity of $108.5 million.
- The company had no interest-bearing liabilities. Operating lease liabilities totaled $2.3 million.
- Accumulated deficit was $131.6 million. No product gross margin is applicable because the company had no product revenue.
Material changes and business developments
- Net loss nearly doubled from 2021, primarily as R&D spending increased by $34.7 million. Management attributed the increase mainly to clinical and preclinical work, manufacturing, and higher headcount. G&A rose by $7.3 million, including higher personnel and public-company costs.
- Operating cash use increased by $27.0 million. Cash, cash equivalents, and restricted cash declined to $112.3 million from $146.1 million; investment maturities provided $27.3 million of net investing cash in 2022.
- The lead candidate, BMF-219, was under evaluation in three clinical studies spanning hematologic cancers, KRAS-mutant solid tumors, and type 2 diabetes. The oncology studies were early-stage; the filing reports no clinical efficacy results for those programs as of year-end.
- Biomea nominated BMF-500, a preclinical covalent FLT3 inhibitor, in 2022. It expected to submit an IND in the first half of 2023 and nominate a third development candidate in that period.
Outlook, commentary, and principal risks
- Going concern: Management concluded that year-end resources would not fund operating expenses and capital requirements for at least 12 months after issuance of the financial statements. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on raising additional capital; availability and terms are uncertain.
- The company had an effective shelf registration for up to $350 million of securities and an at-the-market program for up to $100 million. It reported no ATM sales through the filing. Equity financing could dilute shareholders; debt, collaborations, or licensing could impose restrictions or require relinquishing rights.
- Management expects losses and expenses to rise as it advances trials and research programs. No specific revenue or profitability guidance was provided.
- Major risks include clinical and regulatory failure or delay, unproven translation of preclinical findings to human outcomes, candidate safety and tolerability, competition, reliance on third-party clinical and manufacturing providers, single-source suppliers, and intellectual-property uncertainty. The company had no material legal proceedings.
- The filing also reports preliminary March 2023 COVALENT-111 type 2 diabetes results after four weeks: median HbA1c change was -1.0% in the no-food BMF-219 cohort (n=9) and -0.3% in the with-food cohort (n=10); placebo patients (n=4) showed median and mean reductions between -0.1% and -0.15%. The company reported generally good tolerability in these cohorts, with mostly Grade 1 events and one Grade 2 lipase finding considered unrelated. These are small, early topline results, not evidence of durable benefit or confirmed efficacy.
Most important facts for investors to verify
- Whether the company secures financing sufficient to address the disclosed going-concern uncertainty, and the resulting dilution or other financing terms.
- Complete, longer-term COVALENT-111 data, including HbA1c durability, safety, dose and food effects, and whether preliminary results are replicated.
- Clinical safety and efficacy data from BMF-219 oncology trials; the filing provides preclinical claims but no oncology clinical efficacy results as of year-end.
- Actual timing and progress of BMF-500’s IND and the planned third-candidate nomination, alongside associated spending.
- Cash burn, investment liquidity, trial and manufacturing costs, and any material changes to supply, competition, or patent protection.